Health Report Equatorial Guinea: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Report Equatorial Guinea.

Press releases published on October 14, 2026

21 minutes ago

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

Indeterminate GlobeNewswire

21 minutes ago

BreathiZen Introduces BreathiZen Spray With Mullein Leaf Extract, Ginger Root Extract, Bromelain, and Organic Lemon Extract 60 ml

Indeterminate GlobeNewswire

22 minutes ago

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

Indeterminate GlobeNewswire

22 minutes ago

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Indeterminate GlobeNewswire

22 minutes ago

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer

Indeterminate GlobeNewswire

22 minutes ago

Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome

Indeterminate GlobeNewswire

22 minutes ago

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

Indeterminate GlobeNewswire

22 minutes ago

Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise

Indeterminate GlobeNewswire

22 minutes ago

Elion Therapeutics Expands Pipeline with Exclusive Global License to Inhaled Antifungal for Immunocompromised Patients

Indeterminate GlobeNewswire

22 minutes ago

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

Indeterminate GlobeNewswire

32 minutes ago

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Indeterminate GlobeNewswire

an hour ago

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Indeterminate GlobeNewswire

an hour ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Indeterminate GlobeNewswire

2 hours ago

Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI

Indeterminate GlobeNewswire

3 hours ago

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Indeterminate GlobeNewswire

3 hours ago

Engitix appoints Ryan Richardson to Board of Directors as company advances towards clinical development

Indeterminate GlobeNewswire

3 hours ago

seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases

Indeterminate GlobeNewswire

3 hours ago

Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets

Indeterminate GlobeNewswire

4 hours ago

Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026

Indeterminate GlobeNewswire

5 hours ago

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Indeterminate GlobeNewswire